Drug Profile
Research programme: G protein-coupled receptor agonists - Pfizer
Latest Information Update: 16 Mar 2022
Price :
$50
*
At a glance
- Originator Arena Pharmaceuticals
- Developer Pfizer
- Class Small molecules
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 11 Mar 2022 Arena Pharmaceuticals has been acquired and merged into Pfizer
- 04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 20 Apr 2007 Preclinical development is ongoing for small molecule compounds that mimic the agonist activity of niacin as ligands of G protein-coupled receptors